Figure 1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors

Q: What type of study is this?

This is a Phase 1 study (also classified as: Phase 2).

Omid Hamid; Dana B. Cardin; F. Stephen Hodi; Patricia LoRusso; Taha Merghoub; Roberta Zappasodi; Rachana Maniyar; John E. Janik; Manfred Velden; Feng Zhou; Zhiwan Dong; Xuejun Chen; James J. Harding

doi:10.1158/1078-0432.30255725

October 1, 2025Open Access

Figure 1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors

View Full Paper

Ask AI

Bookmark

Share

Key Points

Only two patients completed treatment, indicating challenges in patient retention and drug tolerance.
Death due to dyspnea was noted in one cohort; 39% of patients were ineligible due to medical history and lab parameters.
Key exclusion reasons included central nervous system metastases and infection risks from HBV or HCV.
Study findings highlight the importance of strict eligibility criteria in clinical trials for advanced cancer therapies.

Implication

Phase I/II study evaluates a glucocorticoid-induced TNF receptor agonist in patients with metastatic solid tumors, suggesting potential treatment avenues.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hamid et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a2195c https://doi.org/10.1158/1078-0432.30255725

View Full Paper

Ask AI

Bookmark

Share

Figure 1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure 1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers